BHVN News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BH

Mkt Cap

$1.63B

Volume

1.84M

Next Earnings

November 9th

Loading chart

BH

BHVNBiohaven Ltd.

BHVN

Pay with—

Available Balance0.00

BH

Mkt Cap

$1.63B

Volume

1.84M

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug DevelopmentBexorg, a precision neurology company, received up to $28.3 million in funding from ARPA-H to extend its BrainEx perfusion technology from 24 hours to two weeks. This advancement will enable longitudinal studies of human brain pharmacology and drug responses, potentially reducing CNS drug development attrition by providing richer human brain data for AI model training and clinical trial design.GlobeNewswire Inc. · Oct 7, 2026

Why Biohaven Stock Was Rocking the Market This WeekBiohaven announced a licensing and collaboration deal with SK Biopharmaceuticals worth up to $795 million for exclusive worldwide rights to its Kv7 ion channel platform and lead drug candidate opakalim for focal epilepsy treatment. Additionally, Biohaven and Yale University won a $4 million judgment in a trade secret misappropriation lawsuit against Avilar Therapeutics and RA Capital Management. These developments drove Biohaven stock up more than 16% week-to-date.The Motley Fool · Aug 28, 2026

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround PotentialSarissa Capital Management established a new $5.79 million position in clinical-stage biotech Biohaven, acquiring 513,184 shares during Q4 2025. Despite the stock falling 70% over the past year due to FDA rejection of troriluzole and disappointing trial results, the fund's investment signals potential turnaround prospects. Biohaven has refocused on late-stage programs including a degrader platform and Phase 2 obesity candidate with data expected in H2 2026, while maintaining a strengthened balance sheet with $500.9 million in cash.The Motley Fool · Mar 23, 2026

Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should KnowBiohaven shares surged 6.65% in regular trading and 3.42% in after-hours trading following an investor presentation at the J.P. Morgan Healthcare Conference. The company presented Phase 1 data for BHV-1400 showing significant reductions in IgA nephropathy markers and clinical improvements in patients. Multiple catalysts are expected in 2026, including Phase 2 obesity trial results, pivotal epilepsy trial results, and initiation of trials for other candidates. However, the stock has declined 67.11% over the past 12 months and is trading near its 52-week lows.Benzinga · Jan 15, 2026

Stock Market Today: Dow Jones, S&P 500, Nasdaq Futures Decline After Christmas Day—Nvidia, Sobr Safe, Biohaven In Focus (UPDATED)U.S. stock futures declined on Friday following Wednesday's gains, with major indices showing modest losses. Key movers included Nvidia rising on a licensing agreement with Groq, Dynavax surging 38% on Sanofi acquisition news, Sobr Safe dropping 16% after announcing a private placement, and Biohaven plummeting 14% after a failed clinical trial. Economist Justin Wolfers cautioned that U.S. market gains are lagging global markets significantly.Benzinga · Dec 26, 2025

Migraine Clinical Trial Pipeline Expands as 30+ Companies Driving Innovation in Oncology Therapeutics Space | DelveInsightThe migraine therapeutics market is experiencing strong growth, with over 30 companies developing innovative treatments targeting migraine through advanced therapies like CGRP inhibitors and gepants, supported by improved diagnostic recognition and patient awareness.GlobeNewswire Inc. · Dec 2, 2025

Biohaven's Chief Accounting Officer Scooped Up 17,000 Shares. Is the Stock a Buy?Biohaven's Chief Accounting Officer George Clark purchased 17,000 shares despite the company facing challenges, including FDA rejection of its lead drug and significant quarterly losses. The stock is currently not recommended for investment due to precarious business outlook.The Motley Fool · Nov 19, 2025

Bexorg Raises $42.5M to Transform CNS Drug Development with World’s First Integrated AI and Whole-Human Brain PlatformBexorg, a biotech startup, secured $42.5M in funding to develop an AI-powered platform for central nervous system drug discovery using whole human brain data, aiming to reduce the historically high clinical trial failure rates in CNS drug development.GlobeNewswire Inc. · Oct 15, 2025

10 Health Care Stocks With Whale Alerts In Today's SessionMultiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.Benzinga · Sep 29, 2025

BHVN FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Biohaven Ltd. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action – BHVNRosen Law Firm is notifying Biohaven Ltd. investors about a securities class action lawsuit alleging false statements regarding drug development prospects for troriluzole and BHV-7000.GlobeNewswire Inc. · Sep 12, 2025

to start trading

BH

BHVNBiohaven Ltd.

BHVN

Pay with—

Available Balance0.00

Your PositionYou don't own any BHVN yet.

Related Tickers

Earnings